Brokers Issue Forecasts for Bellerophon Therapeutics Inc.’s Q1 2017 Earnings (BLPH)
Bellerophon Therapeutics Inc. (NASDAQ:BLPH) – Equities research analysts at SunTrust Banks issued their Q1 2017 earnings per share estimates for Bellerophon Therapeutics in a report issued on Thursday. SunTrust Banks analyst E. Nash expects that the firm will post earnings per share of ($0.27) for the quarter. SunTrust Banks also issued estimates for Bellerophon Therapeutics’ Q2 2017 earnings at ($0.27) EPS, Q3 2017 earnings at ($0.27) EPS and Q4 2017 earnings at ($0.27) EPS.
A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 15th. Cowen and Company reissued a “buy” rating on shares of Bellerophon Therapeutics in a research note on Thursday, August 11th.
Shares of Bellerophon Therapeutics (NASDAQ:BLPH) opened at 0.98 on Friday. Bellerophon Therapeutics has a 12 month low of $0.86 and a 12 month high of $4.58. The company’s market capitalization is $14.31 million. The firm’s 50-day moving average is $1.30 and its 200 day moving average is $1.56.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Stock Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related stocks with our FREE daily email newsletter.